COMMUNIQUÉS West-GlobeNewswire
-
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/07/2026 -
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
02/07/2026 -
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
02/07/2026 -
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
02/07/2026 -
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
02/07/2026 -
Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform
02/07/2026 -
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
02/07/2026 -
Vireo Growth Inc. Announces Pennsylvania Dispensary License Transaction, Expanding into its 11th State
02/07/2026 -
Cannabix Technologies Announces Detection of Methamphetamine and Amphetamine in Human Breath
02/07/2026 -
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
02/07/2026 -
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
02/07/2026 -
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
02/07/2026 -
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
02/07/2026 -
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer
02/07/2026 -
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026 -
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026 -
The Ensign Group Purchases Real Estate and Operations in Texas
02/07/2026 -
Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
02/07/2026 -
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
02/07/2026
Pages